Likarda
PrivateLast Round
Grant
Nov 19, 2025
Total Funding Raised
$4.33M
Momentum Score
25 /100
Company Overview
Likarda is a biotechnology company that provides a hydrogel-based platform, Core-Shell Spherification® (CSS®), for the encapsulation and delivery of cell therapies, biologics, and small molecules to partner biotech and pharmaceutical companies.
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Likarda Comps
Public and private peers based on sector, stage, and business model.
Likarda Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 19, 2025 | ||||
| Grant | Feb 1, 2025 | ||||
| Grant | Sep 7, 2021 | ||||
| Series A | Nov 7, 2017 |
Likarda Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Werth Family Investment Associates | Series A |
| Bill & Melinda Gates Foundation | Grant |
| BioTools Innovator VANGUARD | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 25, 2026
Monthly visitors increased 41% MoM.
- Jan 7, 2026
Monthly visitors increased 41% MoM.
Likarda Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Likarda's valuation, stock price, and market status.
